GeneSys: the new gold standard
GeneSys was born from the need to provide an innovative and rapid PCR-based technology solution for infection monitoring, starting with urinary tract infections.
Benefits of using GeneSys:
Optimization of operating costs
The direct costs of urinary tract infections can be as high as 7,000 per hospitalization.
Service optimization
By reducing the risk of complications, which typically involve 46 percent of patients with urinary tract infections, staff nursing time is optimized.
Waste reduction
Currently, 70% of urinary tract infections require at least 10 days of antibiotic treatment. Through early detection, treatment can be reduced with a positive impact on the patient and accounts.
Improved quality of life
Complications from urinary tract infections can lead to dialysis, cognitive impairment, and reduced patient autonomy.
With the possibility of rapid and continuous monitoring, long-term effects can be prevented, improving patients’ lives.
Urinary tract infections: a cost to society and national health systems
In Italy, urinary tract infections are one of the leading causes of nosocomial infection in hospitals and other health care facilities.
According to data from the Italian Ministry of Health, 14,566 nosocomial urinary tract infections were reported in 2020, with an incidence rate of 8.5 cases per 1,000 inpatient days.
In Europe and around the world, urinary tract infections are also an important public health problem with significant health care costs.
According to a study published in the journal “PLoS ONE” in 2018, healthcare-associated urinary tract infections caused 2.5 million additional hospital days and additional costs of 676 million euros in European Union countries in 2015.
